{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/urethritis-male/prescribing-information/doxycycline/","result":{"pageContext":{"chapter":{"id":"6598b6d1-3e66-518c-9a8b-63eff17fecaf","slug":"doxycycline","fullItemName":"Doxycycline","depth":2,"htmlHeader":"<!-- begin field 69b7e832-6bec-49ae-ba60-fd28181c17c7 --><h2>Doxycycline</h2><!-- end field 69b7e832-6bec-49ae-ba60-fd28181c17c7 -->","summary":"","htmlStringContent":"<!-- begin item b75e133e-629b-41a2-ac31-dc44998ca26c --><!-- end item b75e133e-629b-41a2-ac31-dc44998ca26c -->","topic":{"id":"f36465a1-1338-5604-8bb2-c8e555c598ae","topicId":"9d634e3c-7474-4d96-bbcb-7c29c10c1b03","topicName":"Urethritis - male","slug":"urethritis-male","lastRevised":"Last revised in September 2019","chapters":[{"id":"ac50911c-3aae-5117-95ce-67557d49723a","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"ae05a825-47bf-5fc0-9065-c859d8427b3b","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"1c94ea5f-b73f-51a3-9d99-83814d055e3f","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"8e3d5f57-add8-5b6f-bd13-9ea05bc5ec30","slug":"changes","fullItemName":"Changes"},{"id":"7353c5be-d0ed-506f-8487-265ce270e97f","slug":"update","fullItemName":"Update"}]},{"id":"644de86f-bfeb-5ebf-8cda-c1be15f8938a","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"bd23c29c-af09-54b6-be4e-9f6ed812d62a","slug":"goals","fullItemName":"Goals"},{"id":"63346f4c-c71f-5887-b6d3-0d07661b1393","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"49121260-b8cb-5ecc-855a-f87303bc727e","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"40b6a387-e841-594d-8616-fb4e8f4391e1","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"7d3a51c9-f614-5196-8052-55ceb4b6cf08","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"b2b68ef0-16c8-5dbc-b8f8-fbdfa673ed3f","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"027c2bf3-1625-560c-902b-9fef54935849","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"95898c97-d200-5648-b696-7388ab850318","slug":"definition","fullItemName":"Definition"},{"id":"9b0e6aa9-b665-52de-bfa3-93f09f83bc3d","slug":"causes","fullItemName":"Causes"},{"id":"f9c36294-6c74-5b9e-8afb-65b38bfa14e1","slug":"prevalence","fullItemName":"Prevalence"},{"id":"2d0fc428-15ca-543a-bd93-b4ac231ed0cb","slug":"complications-prognosis","fullItemName":"Complications and prognosis"}]},{"id":"b7be062a-0eff-5e83-9493-809927e4776a","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"60b1f452-fec4-567e-b8f0-39660841e61b","slug":"when-to-suspect-urethritis","fullItemName":"When to suspect urethritis"},{"id":"d5d984a2-a3d7-533a-9b94-02ac51c4fa07","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"75471ada-cb93-59f3-97b0-3c182e9f80b7","fullItemName":"Management","slug":"management","subChapters":[{"id":"b6607a10-84f2-51a2-ac03-a68ccb8dcbe9","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"513fcd9d-25a9-5183-98b5-32bdef8e6d5a","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"6598b6d1-3e66-518c-9a8b-63eff17fecaf","slug":"doxycycline","fullItemName":"Doxycycline"},{"id":"c498c9de-1083-50a6-b290-ac30aebda851","slug":"azithromycin","fullItemName":"Azithromycin"},{"id":"ecf258dc-1499-5f7a-a781-6566ea1a4f54","slug":"ofloxacin","fullItemName":"Ofloxacin"},{"id":"f4c18a1e-b367-5433-ac91-efd9bce81a5e","slug":"metronidazole","fullItemName":"Metronidazole"}]},{"id":"221c9f46-f915-5e6f-8275-959420090646","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"25917416-1fc8-5919-9773-f3b7e054b6a0","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"2ad44d6a-7cb1-598d-9dd4-9552f4f7fb49","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"791a5ccc-3882-5e9e-a55e-fc18bff5d67a","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"7370a44f-6a25-58d8-a772-568023fd6516","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"991288b5-d1b7-50f9-8e87-ceaf3331e0e2","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"bf8f6743-57dd-5f6e-9460-bbecad8fd0b5","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"b2d086b7-cf3d-5d24-994a-e0280f2397db","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"513fcd9d-25a9-5183-98b5-32bdef8e6d5a","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"edbbe8a8-e69c-5e82-8243-1624d6e4a646","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field b815dca7-09b3-4c48-86cf-8c6034726bb0 --><h3>Contraindications and cautions</h3><!-- end field b815dca7-09b3-4c48-86cf-8c6034726bb0 -->","summary":"","htmlStringContent":"<!-- begin item 1c8b1b90-0385-40d8-9a10-19b8c00732d7 --><!-- begin field 3698ac1c-2a13-4b3f-936a-d403e1e078d3 --><ul><li><strong>Do not prescribe doxycyline to people with:</strong><ul><li>Known hypersensitivity to any of the tetracyclines.</li><li>Acute porphyria.</li><li>Systemic lupus erythematous — tetracyclines may exacerbate systemic lupus erythematosus.</li></ul></li><li><strong>Prescribe doxycyline with caution in people with myasthenia gravis</strong> — tetracyclines may increase muscle weakness in people with myasthenia gravis.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/urethritis-male/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urethritis-male/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 3698ac1c-2a13-4b3f-936a-d403e1e078d3 --><!-- end item 1c8b1b90-0385-40d8-9a10-19b8c00732d7 -->","subChapters":[]},{"id":"993c4610-6560-51b1-b146-03111126d955","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 3ca0ca9a-a06a-4ba3-b89a-3bbca1fc45f4 --><h3>Adverse effects</h3><!-- end field 3ca0ca9a-a06a-4ba3-b89a-3bbca1fc45f4 -->","summary":"","htmlStringContent":"<!-- begin item 32787124-f947-4461-bda0-926c74609dfe --><!-- begin field 3cc56307-bc02-4cb4-ac75-1e26f6cf9b6a --><ul><li><strong>Gastrointestinal — </strong>doxycycline is a broad-spectrum antibiotic and has the potential to cause nausea, vomiting, and diarrhoea.</li><li><strong>Photosensitivity — </strong>less frequently, doxycycline may cause photosensitivity. People taking doxycycline should be warned to avoid direct exposure to natural or artificial sunlight and to discontinue treatment at the first sign of skin discomfort [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urethritis-male/references/\">Wolf, 2002</a>].</li><li><strong>Benign intracranial hypertension — </strong>this is a rare but important adverse effect of tetracyclines. If a person taking doxycyline develops headache and visual disturbance, the drug should be stopped immediately.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/urethritis-male/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urethritis-male/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 3cc56307-bc02-4cb4-ac75-1e26f6cf9b6a --><!-- end item 32787124-f947-4461-bda0-926c74609dfe -->","subChapters":[]},{"id":"295f459e-9914-5bc0-8f75-8bbc9e6660f0","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 2c2ee71e-9cf7-4128-b54e-aac90108d6dc --><h3>Drug interactions</h3><!-- end field 2c2ee71e-9cf7-4128-b54e-aac90108d6dc -->","summary":"","htmlStringContent":"<!-- begin item 5b996499-d56b-41f8-87d9-aac90108d638 --><!-- begin field 877e32f3-45f2-4ae1-9fc7-aac90108d6dc --><p><strong>Key drug interactions with doxycycline include:</strong></p><ul><li><strong>Antacids</strong> (containing aluminium, bismuth, calcium, or magnesium) and other medications containing iron or zinc — these reduce the absorption of tetracyclines if taken concurrently.<ul><li>Avoid taking antacids and other medications containing iron or zinc, 2 hours before or after taking tetracyclines.</li></ul></li><li><strong>CYP3A enzyme inducers</strong> (phenobarbital, carbamazepine or phenytoin) — these may reduce the serum half-life of doxycycline.<ul><li>Monitor and adjust the dose if necessary.</li></ul></li><li><strong>Insulin</strong> — the blood-glucose lowering effect may be increased if taken with doxycycline.<ul><li>Monitor blood-glucose levels.</li></ul></li><li><strong>Lithium</strong> — levels may be increased by doxycycline.<ul><li>Consider increasing the frequency of lithium monitoring.</li></ul></li><li><strong>Methotrexate </strong>— levels may be increased by doxycycline.</li><li><strong>Retinoids</strong> — there is a possible increased risk of benign intracranial pressure if tetracyclines are used concurrently with retinoids (such as isotretinoin).<ul><li>Avoid the concurrent use of tetracyclines and retinoids.</li></ul></li><li><strong>Rifampicin</strong> — doxycycline levels are markedly reduced, which may lead to treatment failure.<ul><li>Monitor the effects and increase doxycycline dose if necessary.</li></ul></li><li><strong>Warfarin</strong> — the concurrent use of warfarin with tetracyclines may increase the anticoagulant effect. However, there is little evidence to suggest clinical relevance.<ul><li>Consider monitoring the person's international normalized ratio (INR) regularly and within 3 days of starting the tetracycline. Adjust the warfarin dose accordingly.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/urethritis-male/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urethritis-male/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 877e32f3-45f2-4ae1-9fc7-aac90108d6dc --><!-- end item 5b996499-d56b-41f8-87d9-aac90108d638 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}